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Diﬀerentiation of Cardiac from Noncardiac Pleural Eﬀusions in Cats
using Second-Generation Quantitative and Point-of-Care
NT-proBNP Measurements
M.J. Hezzell, J.E. Rush, K. Humm, E.A. Rozanski, J. Sargent, D.J. Connolly, A. Boswood, and
M.A. Oyama
Background: Pleural eﬀusion is a common cause of dyspnea in cats. N-terminal pro-B-type natriuretic peptide (NT-
proBNP) measurement, using a ﬁrst-generation quantitative ELISA, in plasma and pleural ﬂuid diﬀerentiates cardiac from
noncardiac causes of pleural eﬀusion.
Hypothesis/Objectives: To determine whether NT-proBNP measurements using second-generation quantitative ELISA
and point-of-care (POC) tests in plasma and pleural ﬂuid distinguish cardiac from noncardiac pleural eﬀusions and how
results compare to the ﬁrst-generation ELISA.
Animals: Thirty-eight cats (US cohort) and 40 cats (UK cohort) presenting with cardiogenic or noncardiogenic pleural
eﬀusion.
Methods: Prospective cohort study. Twenty-one and 17 cats in the US cohort, and 22 and 18 cats in the UK cohort were
classiﬁed as having cardiac or noncardiac pleural eﬀusion, respectively. NT-proBNP concentrations in paired plasma and
pleural ﬂuid samples were measured using second-generation ELISA and POC assays.
Results: The second-generation ELISA diﬀerentiated cardiac from noncardiac pleural eﬀusion with good diagnostic accu-
racy (plasma: sensitivity, 95.2%, speciﬁcity, 82.4%; pleural ﬂuid: sensitivity, 100%, speciﬁcity, 76.5%). NT-proBNP concen-
trations were greater in pleural ﬂuid (719 pmol/L (134–1500)) than plasma (678 pmol/L (61–1500), P = 0.003), resulting in
diﬀerent cut-oﬀ values depending on the sample type. The POC test had good sensitivity (95.2%) and speciﬁcity (87.5%)
when using plasma samples. In pleural ﬂuid samples, the POC test had good sensitivity (100%) but low speciﬁcity (64.7%).
Diagnostic accuracy was similar between ﬁrst- and second-generation ELISA assays.
Conclusions and clinical importance: Measurement of NT-proBNP using a quantitative ELISA in plasma and pleural ﬂuid
or POC test in plasma, but not pleural ﬂuid, distinguishes cardiac from noncardiac causes of pleural eﬀusion in cats.
Key words: Biomarker; Blood testing; Cardiomyopathy; Dyspnea; Natriuretic peptide.
Dyspnea secondary to pleural eﬀusion is a commonpresenting complaint in cats, and can be the result
of a variety of disease processes, including neoplasia,
cardiac disease, pyothorax, and feline infectious peri-
tonitis.1,2 Diﬀerentiation of the underlying causes can
be challenging in dyspneic cats. These cats might
require supplementary oxygen and be too unstable to
tolerate extensive diagnostic testing. Measurement of
N-terminal pro-B-type natriuretic peptide (NT-proBNP)
using a ﬁrst-generation feline-speciﬁc quantitative ELI-
SAa in plasma3,4 and pleural ﬂuid4 samples diﬀerenti-
ates cardiac from noncardiac causes of pleural eﬀusion
in cats. Measurement in pleural ﬂuid samples is a
potentially attractive alternative to measurement in
plasma, insofar as therapeutic thoracocentesis is usually
performed in cats with signiﬁcant pleural eﬀusion,
whereas venipuncture might cause additional distress to
an already dyspneic cat. In human patients, measure-
ment of NT-proBNP concentrations in pleural ﬂuid has
high diagnostic accuracy to distinguish cardiac from
noncardiac causes of pleural eﬀusion. Meta-analysis of
1,120 human patients revealed high sensitivity (94%,
95% conﬁdence interval [CI]: 90–97%) and speciﬁcity
(94%, 95% CI: 89–97%) with a strong correlation
between NT-proBNP concentrations measured in
plasma and pleural ﬂuid samples.5
Second-generation assays that measure NT-proBNP
in cats are available, including a second-generation
quantitative ELISAa and a semiquantitative point-
of-care (POC) testb that is speciﬁcally designed for
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detection of preclinical or occult forms of cardiomyopa-
thy.6 In contrast to the ﬁrst-generation assay, sample
collection for the second-generation assays is performed
without the use of a protease inhibitor cocktail and spe-
cial handling and shipping requirements.c In emergent
cats, one disadvantage of the ELISA assay that is run
at a reference laboratory is that results are usually not
available until 1–2 working days after sample submis-
sion. The POC test oﬀers patient-side semiquantitative
measurement of NT-proBNP but its utility to distin-
guish cardiac from noncardiac causes of pleural eﬀusion
using either plasma or pleural ﬂuid samples has not
been investigated.
The aims of this study were to determine whether
measurement of NT-proBNP in plasma or pleural ﬂuid
samples using either the second-generation quantitative
ELISA or POC assay could distinguish cardiac from
noncardiac causes of pleural eﬀusion, and how these
results compared to the results of a previous study
using the ﬁrst-generation quantitative ELISA assay.4
Materials and Methods
The study was approved by the respective institutional animal
use and care committees and informed owner consent was
obtained. Thirty-eight cats presenting to one of two US teaching
hospitals (Matthew J. Ryan Veterinary Hospital of the University
of Pennsylvania, Philadelphia PA and the Foster Hospital for
Small Animals, Cummings School of Veterinary Medicine, Tufts
University, North Grafton, MA) with pleural eﬀusion undergoing
thoracocentesis were prospectively recruited (US cohort). Forty
cats presenting to a UK teaching hospital (Queen Mother Hospital
for Animals, Royal Veterinary College, North Mymms, Hatﬁeld)
with pleural eﬀusion undergoing thoracocentesis were prospec-
tively recruited, as previously described (UK cohort).4 For both
cohorts, cats were recruited and the cause of the pleural eﬀusion
was determined to be either cardiac or noncardiac by a board-cer-
tiﬁed cardiologist on the basis of the echocardiogram, history,
physical examination, and results of any additional diagnostic tests
performed. The cardiologist was blinded to all quantitative and
POC measurements of NT-proBNP.
Pleural ﬂuid samples were obtained at the time of therapeutic
or diagnostic thoracocentesis. Plasma samples were collected when
venipuncture for diagnostic sampling was performed during the
same hospital visit and as close to the time of therapeutic thoraco-
centesis as was clinically practicable on the basis of feline stability.
One milliliter samples of pleural ﬂuid and 2 milliliter samples of
blood were collected in K2-EDTA treated tubes and were cen-
trifuged at 3000 9 g for 5 minutes within 15 minutes of collection.
For the US cohort, NT-proBNP was measured in plasma using
the POC assayb within 30 minutes of centrifugation and the
remaining plasma and pleural ﬂuid samples were each transferred
to a cryotube and frozen at 80°C for batched analysis. NT-
proBNP was measured at the reference laboratory in plasma and
pleural ﬂuid samples using the second-generation ELISAa and in
pleural ﬂuid samples using the POC assay. b For the UK cohort,
which was originally recruited for assessment of the ﬁrst-genera-
tion NT-proBNP ELISA assay,4 NT-proBNP was measured at the
reference laboratory in plasma and pleural ﬂuid samples using the
second-generation ELISAa and POC assayb in samples collected in
a protease inhibitor tubec and frozen at 80°C for batched
analysis.
The second-generation NT-proBNP in cat assays incorporate a
set of antibodies diﬀerent from the ﬁrst-generation assay that
attempt to target stable epitopes of NT-proBNP in cats.d The
lower and upper limits of detection of the reference laboratory
assay are 24 pmol/L and 1500 pmol/L, respectively. Values of NT-
proBNP less than the lower limit of detection were assigned values
of 24 pmol/L. Values of NT-proBNP greater than the upper limit
of detection were assigned values of 1500 pmol/L. All reference
laboratory samples were assayed in duplicate and the mean of the
two values used.
The POC test is a bidirectional ﬂow ELISA that uses the same
pair of antibodies for the detection of NT-proBNP in cats as the
second-generation reference laboratory test, and its use in detect-
ing occult cardiomyopathy has been previously described.6 Brieﬂy,
to perform the POC assay, 3 drops of plasma or pleural ﬂuid were
mixed with 5 drops of assay conjugate and then added to the sam-
ple well of the test device. The conjugate-diluted sample was
allowed to ﬂow across the device. Once the sample reached the
indicator window, the device was activated by the operator. This
initiated the wash and color development steps of the assay. The
relative color densities of the sample and reference spots were eval-
uated visually after 10 minutes of incubation. Positive results were
recorded when the density of the sample spot appeared equal to or
greater than that of the reference spot. Negative results were
recorded when the density of the sample spot appeared less than
that of the reference spot. The transition from negative to
positive on the POC test occurs in an NT-proBNP range of 150–
200 pmol/L.6
Statistical Analysis
Statistical analysis was performed using commercially available
software.e Data were examined graphically for normality of distri-
bution. Group-wise comparisons were performed using Mann–
Whitney tests, Wilcoxon signed-rank tests, or Fisher’s exact test,
as appropriate. Receiver operator characteristic (ROC) curves were
constructed to derive cut-oﬀs for diﬀerentiation of cardiac from
noncardiac causes of pleural eﬀusion in plasma and pleural ﬂuid
samples based on results from the US cohort. Sensitivity, speci-
ﬁcity, and positive and negative likelihood ratios were calculated.
The positive likelihood ratio is the ratio of true positives to false
positives and the negative likelihood ratio is the ratio of false neg-
atives to true negatives. A positive likelihood ratio <5 is consid-
ered a reasonable diagnostic test for ruling in a condition and a
negative likelihood ratio less than 0.2 is considered a reasonable
diagnostic test for ruling out a condition.7 By prespeciﬁed design,
the cut-oﬀ values generated from the US cohort were subsequently
tested in the UK cohort. Spearman’s rank order correlation coeﬃ-
cients (rho) and Bland–Altman plots were used to compare quanti-
tative ELISA measurements of NT-proBNP between plasma and
pleural ﬂuid samples and the ﬁrst- and second-generation assays.8
Results
Thirty-eight cats with pleural eﬀusion were enrolled
in the US cohort between February and November
2014. Twenty-one cats were assigned to the cardiac
group and 17 cats were assigned to the noncardiac
group. The population characteristics of the US cohort
are presented in Table 1. No diﬀerences were detected
between groups for age, breed, body weight, heart rate,
respiratory rate, or diastolic measurements of interven-
tricular septum and left ventricular free wall thickness
(IVSd and LVFWd, respectively). Cats in the cardiac
group had signiﬁcantly greater left atrial to aortic root
ratios (LA/Ao), and were signiﬁcantly more likely to be
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male, to have a murmur or to have a gallop rhythm on
auscultation.
Forty cats with pleural eﬀusion were enrolled in the
UK cohort between February 2011 and June 2012. The
study population and utility of NT-proBNP concentra-
tion using the ﬁrst-generation assay have been described
previously.4 Twenty-two cats were assigned to the car-
diac group and 18 cats were assigned to the noncardiac
group. A cut-oﬀ of 213.3 pmol/L in plasma samples
had a sensitivity of 86.4% (95% conﬁdence interval
(CI) 66.7–95.3%) and speciﬁcity of 88.9% (95% CI
67.2–96.9%), and a cut-oﬀ of 322.3 pmol/L in pleural
ﬂuid samples had a sensitivity of 100% (95% CI 85.1–
100.0%) and a speciﬁcity of 94.4% (74.2–99%) to dis-
tinguish cardiac from noncardiac causes of pleural eﬀu-
sion. Samples were stored at 80°C for 30–46 months
before analysis.
Results of NT-proBNP measurements in the US
cohort using the second-generation reference laboratory
ELISA and the POC test are presented in Table 2. The
result of the POC test using a plasma sample was not
available for one cat in the noncardiac group. NT-
proBNP concentrations in plasma and pleural ﬂuid
samples were signiﬁcantly higher in the cardiac group
than in the noncardiac group (P < 0.0001). The propor-
tion of positive POC results from both plasma and
pleural ﬂuid samples was signiﬁcantly higher in the car-
diac group than in the noncardiac group (P < 0.0001).
ROC curve analysis in the US cohort revealed an opti-
mal plasma NT-proBNP cut-oﬀ of ≥199 pmol/L with a
sensitivity of 95.2% (95% CI 77.3–99.2%), speciﬁcity of
82.4% (95% CI 59.0–93.8%), positive likelihood ratio
of 5.40 (95% CI 1.92–15.14), and negative likelihood
ratio of 0.06 (95% CI 0.01–0.40). The area under the
ROC curve was 0.952 (95% CI 0.891–1.00). A pleural
ﬂuid NT-proBNP cut-oﬀ of ≥240 pmol/L yielded a sen-
sitivity of 100% (95% CI 84.5–100%), speciﬁcity of
76.5% (95% CI 52.7–90.4), and positive likelihood ratio
of 4.25 (95% CI 1.80–10.01). The negative likelihood
ratio could not be calculated because all 21 cats with
pleural eﬀusion of cardiac origin had pleural ﬂuid NT-
proBNP ≥240 pmol/L. The area under the pleural ﬂuid
ROC curve was 0.923 (95% CI 0.832–1.00). There was
no signiﬁcant diﬀerence between the area under the
pleural ﬂuid ROC curve and the area under the plasma
ROC curve (P = 0.26).
In the US cohort, the POC test using plasma sam-
ples diﬀerentiated the cardiac and noncardiac groups
with a sensitivity of 95.2% (95% CI 77.3–99.2%),
speciﬁcity of 87.5% (95% CI 64.0–96.5%), positive
likelihood ratio of 7.62 (95% CI 2.08–27.95), and neg-
ative likelihood ratio of 0.05 (95% CI 0.01–0.37). The
area under the ROC curve for the POC assay using
plasma samples was 0.914 (95% CI 0.818–1.00). The
POC test using pleural ﬂuid samples diﬀerentiated the
cardiac and noncardiac groups with a sensitivity of
100% (95% CI 84.5–100%), speciﬁcity of 64.7% (95%
CI 41.3–82.7%), and positive likelihood ratio of 2.83
(95% CI 1.49–5.39) in the US cohort. The negative
likelihood ratio could not be calculated because all 21
cats with pleural eﬀusion of cardiac origin had a posi-
tive POC assay. The area under the ROC curve for
the POC assay using pleural ﬂuid samples was 0.824
(95% CI 0.706–0.941) and was not statistically diﬀer-
ent from the area under the ROC curve for plasma
samples (P = 0.096).
Results of NT-proBNP measurements in the UK
cohort using the second-generation reference laboratory
ELISA and the POC test are presented in Table 3.
Insuﬃcient plasma sample volume was available to
measure NT-proBNP using the second-generation ver-
sion of the ELISA in 3 cats and using the POC test in 6
cats. When the cut-oﬀ values derived from the US
Table 1. Characteristics of the cardiac and noncardiac groups in the US cohort. The median and ranges are shown
for continuous variables. NB sex was not recorded for one cat in the cardiac group.
Variable Noncardiac (n = 17) Cardiac (n = 21) P value
Age (years) 12.0 (0.5–16.0) 12.0 (1.5–18.0) 0.86
Pedigree breed (yes/no) 2/15 1/20 0.58
Sex (male/female) (n = 37) 6/11 16/4 0.008
Weight (kg) 4.1 (2.1–8.8) 4.9 (2.7–6.9) 0.74
Heart rate (beats per minute) 200 (160–260) 180 (130–300) 0.27
Respiratory rate (breaths per minute) 68 (44–92) 60 (30–88) 0.17
Murmur (yes/no) 5/12 15/6 0.021
Gallop (yes/no) 1/16 13/8 0.001
LA/Ao 1.3 (1.0–1.9) 2.6 (1.6–3.2) <0.001
IVSd (mm) (n = 35) 5.5 (3.5–7.5) 6.2 (3.7–10.0) 0.37
LVFWd (mm) (n = 35) 5.8 (2.9–11.0) 7.2 (3.8–18.6) 0.16
Table 2. Results of NT-proBNP measurements for the
cardiac and noncardiac groups using 2 assay methods
for the US cohort. The median and interquartile ranges
are shown for continuous variables.
Cardiac (n = 21)
Noncardiac
(n = 17) P value
Second-generation ELISA (pmol/L)
Plasma 1500 (790–1500) 58 (31–174.5) <0.0001
Pleural ﬂuid 1500 (918–1500) 108 (56–324.5) <0.0001
Point-of-care test (no. positive/no. negative)
Plasma (n = 37) 20/1 2/14 <0.0001
Pleural ﬂuid 21/0 6/11 <0.0001
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cohort were applied to plasma and pleural ﬂuid mea-
surements of NT-proBNP using the second-generation
assay from the UK cohort, plasma NT-proBNP
≥199 pmol/L yielded a sensitivity of 95.0% (95% CI
76.4–99.1%), speciﬁcity of 82.4% (95% CI 59.0–
93.8%), positive likelihood ratio of 5.40 (95% CI 1.92–
15.11), and negative likelihood ratio of 0.06 (95% CI
0.01–0.42). Pleural ﬂuid NT-proBNP ≥240 pmol/L
yielded a sensitivity of 100% (95% CI 85.1–100%),
speciﬁcity of 66.7% (95% CI 43.8–83.7%), and positive
likelihood ratio of 3.00 (95% CI 1.56–5.77). The nega-
tive likelihood ratio could not be calculated because all
22 cats with pleural eﬀusion of cardiac origin had pleu-
ral ﬂuid NT-proBNP ≥240 pmol/L. For both plasma
and pleural ﬂuid samples, the 95% CI of the sensitivity
and speciﬁcity of the second-generation ELISA assay
overlapped with reported conﬁdence intervals using the
ﬁrst-generation ELISA assay.4 In the UK cohort, the
POC test using plasma samples diﬀerentiated cardiac
from noncardiac causes of pleural eﬀusion with a sensi-
tivity of 88.2% (95% CI 65.7–96.7%), speciﬁcity of
88.2% (95% CI 65.7–96.7%), positive likelihood ratio
of 7.50 (95% CI 2.02–27.89), and negative likelihood
ratio of 0.13 (95% CI 0.04–0.50). The POC test using
pleural ﬂuid samples diﬀerentiated cardiac from noncar-
diac causes of pleural eﬀusion with a sensitivity of
100% (95% CI 85.1–100%), speciﬁcity of 77.8% (95%
CI 54.8–91.0%), and positive likelihood ratio of 4.50
(95% CI 1.89–10.68). The negative likelihood ratio
could not be calculated because all 22 cats with pleural
eﬀusion of cardiac origin had a positive POC assay.
NT-proBNP concentrations in paired plasma and
pleural ﬂuid samples from the US cohort were mea-
sured using the second-generation ELISA assay, and
were signiﬁcantly correlated (Spearman rho = 0.969;
P < 0.0001); however, the limits of agreement between
the two sample types were wide, and NT-proBNP con-
centrations in pleural ﬂuid were systematically greater
than those in plasma samples (pleural ﬂuid, 719 pmol/L
[134–1500] versus plasma, 678 pmol/L [61–1500];
P = 0.003) with a mean bias of +67.9 pmol/L (Fig 1).
NT-proBNP concentrations in plasma samples from the
UK cohort using the ﬁrst- and second-generation
ELISA assay were signiﬁcantly correlated (Spearman
rho = 0.864; P < 0.0001); however, the limits of agree-
ment between the two assay generations were wide, and
NT-proBNP concentrations in plasma assayed using the
second-generation assay were systematically greater
than those in plasma samples assayed using the ﬁrst-
generation assay (plasma second-generation, 531 pmol/
L (84–874) versus plasma ﬁrst-generation 254 pmol/L
(50–620); P = 0.002), with a mean bias of +156.1 pmol/
L (Fig 2). NT-proBNP concentrations in pleural ﬂuid
samples from the UK cohort using the ﬁrst- and sec-
ond-generation ELISA assay were signiﬁcantly corre-
lated (Spearman rho = 0.966; P < 0.0001). Pleural ﬂuid
NT-proBNP concentrations were not signiﬁcantly diﬀer-
ent between the two diﬀerent generations of NT-
proBNP ELISA assay (pleural second generation,
603 pmol/L (121–1135) versus pleural ﬁrst generation
542 pmol/L (142–1374); P = 0.95).
Discussion
This study utilized data from two separate cohorts to
investigate the diagnostic characteristics of a quantita-
tive ELISA and semiquantitative POC test to diﬀerenti-
ate cardiac and noncardiac causes of pleural eﬀusion in
cats. Our results demonstrate that measurement of NT-
proBNP in plasma samples using either a quantitative
ELISA or POC test diﬀerentiates these etiologies of
pleural eﬀusion with good diagnostic accuracy. Mea-
surement of NT-proBNP concentration in pleural ﬂuid
samples using the quantitative ELISA also had good
diagnostic accuracy as long as a higher cut-oﬀ value is
used for pleural ﬂuid samples (≥240 pmol/L) compared
to the cut-oﬀ value used for plasma samples
(≥199 pmol/L). In the emergency setting, POC testing
of either plasma or pleural ﬂuid is attractive because of
the immediacy of assay results. Testing of pleural eﬀu-
sion, speciﬁcally, is attractive in instances in which cats
with signiﬁcant pleural eﬀusion would undergo thera-
peutic thoracocentesis but might not be stable enough
for venipuncture. However, the results of this study sug-
gest that the diagnostic value of POC testing of pleural
eﬀusion samples is limited. Using pleural ﬂuid samples,
a negative POC assay result helped to rule out cardiac
causes of pleural eﬀusion, but a positive result was
associated with a relatively low positive predictive value,
and the likelihood ratio associated with a positive pleu-
ral ﬂuid POC test from either the US or UK cohort
(i.e., 2.83 and 4.5) was lower than the level (i.e. 5.0)
generally considered to indicate a useful diagnostic test.7
Thus, a positive POC result using pleural ﬂuid samples
frequently represents a false positive result, and this lim-
its its diagnostic value. The discrepancy in performance
between testing plasma and pleural ﬂuid samples using
the POC test probably reﬂects the NT-proBNP concen-
tration at which the POC device transitions from a neg-
ative to positive result. A previous study has shown this
to occur at a NT-proBNP concentration between 150
and 200 pmol/L,6 which approximates the cut-oﬀ value
in plasma (199 pmol/L) but is lower than the optimal
cut-oﬀ for pleural ﬂuid samples (240 pmol/L) found in
this study.
Table 3. Results of NT-proBNP measurements for the
cardiac and noncardiac groups using 2 assay methods
for the UK cohort. The median and interquartile ranges
are shown for continuous variables.
Cardiac
(n = 22)
Noncardiac
(n = 18) P value
Second-generation ELISA (pmol/L)
Plasma 849 (590–1500)
(n = 20)
73 (33–138)
(n = 17)
<0.0001
Pleural ﬂuid 1001 (640–1500)
(n = 22)
98 (45–273)
(n = 18)
<0.0001
Point-of-care test (no. positive/no. negative)
Plasma (n = 34) 15/2 2/15 <0.0001
Pleural ﬂuid (n = 40) 22/0 4/14 <0.0001
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Likelihood ratios can be used to estimate post-test
probability of pleural eﬀusion of cardiac cause. In this
study, plasma POC test results were associated with
approximate positive and negative likelihood ratios of
7.50 and 0.10, respectively. These values roughly trans-
late into an absolute increase or decrease in the post-
test probability for a cardiac cause of pleural eﬀusion
of 40% compared to the pretest probability.9 For
example, in a population of cats whose pretest proba-
bility of pleural eﬀusion because of a cardiac cause is
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Fig 1. Bland–Altman plot illustrating agreement between measurements of NT-proBNP concentrations in pleural ﬂuid and plasma sam-
ples in cats using the second-generation assay in samples from the US cohort. The mean bias and the dash-dot lines representing the 95%
conﬁdence intervals for the bias indicate that the NT-proBNP concentration of pleural ﬂuid samples was on average 67.9 pmol/L greater
than NT-proBNP concentration from paired plasma sample. The 95% limits of agreement between the two sample types are displayed as
1.96 times the standard deviation of the diﬀerence.
-500
0
500
1000
1500
0 500 1000 1500 2000
Mean 1st and 2nd Generation Plasma [NT-proBNP]
2n
d 
G
en
er
at
io
n 
- 1
st
 G
en
er
at
io
n 
Pl
as
m
a 
[N
T-
pr
BN
P]
Mean
156.1
-1.96 SD
-398.9
+1.96 SD
711.2
Fig 2. Bland–Altman plot illustrating agreement between measurements of NT-proBNP concentrations in plasma samples from cats using
the ﬁrst- and second-generation assay in samples from the UK cohort. The mean bias and the dash-dot lines representing the 95% conﬁ-
dence intervals for the bias indicate that the NT-proBNP concentration of plasma samples using the second-generation assay was on aver-
age 156.1 pmol/L greater than NT-proBNP concentration from paired plasma sample using the ﬁrst generation assay. The 95% limits of
agreement between the two sample types are displayed as 1.96 times the standard deviation of the diﬀerence.
540 Hezzell et al
60%, a positive plasma POC test would increase this
probability to nearly 100% while a negative plasma
POC test result would reduce the probability to 20%.
Likewise, in a population of cats where a cardiac cause
of pleural eﬀusion is 10%, and hence unlikely, a posi-
tive POC test increases this probability to only 50%. It
is therefore important, as with any clinical test, that
measurements of NT-proBNP be interpreted in combi-
nation with historical and physical examination ﬁndings
and the results of other diagnostic tests such as imaging
and not be relied upon in isolation for clinical decision-
making.
The optimal cut-oﬀs determined in this study are
somewhat lower than those previously reported. Cut-
oﬀs for diﬀerentiation of cardiac from noncardiac
causes of dyspnea using plasma samples have been
reported as 220 pmol/L,10 265 pmol/L,11 214 pmol/L4
and 258 pmol/L.3 The former two studies did not
restrict inclusion to cats with pleural eﬀusion, whereas
the latter two did; all of these studies used the ﬁrst-
generation quantitative ELISA. A cut-oﬀ for pleural
ﬂuid samples of 322 pmol/L has been reported to dis-
tinguish cardiac and noncardiac causes of dyspnea
using the ﬁrst-generation ELISA.4 Given that plasma
measurements of NT-proBNP were found to be higher
using the second- compared with the ﬁrst-generation
ELISA and that no diﬀerence was found in pleural
ﬂuid measurements between assay generations, it seems
surprising that the optimal cut-oﬀs were lower in this
study than those previously reported. However, this
probably reﬂects the relatively small sample sizes in
each study, population diﬀerences (United states ver-
sus United Kingdom versus Germany) and diﬀerences
in the methods used to select the optimal cut-oﬀ val-
ues.
This study revealed that NT-proBNP concentrations
were signiﬁcantly higher in pleural ﬂuid samples than
in plasma samples when measured using the quantita-
tive second-generation ELISA, resulting in the need for
two diﬀerent cut-oﬀ values depending on sample type.
These ﬁndings agree with a previous study that com-
pared pleural ﬂuid and plasma samples in cats using
the ﬁrst-generation assay,4 but are in contrast to
human patients, in whom pleural ﬂuid and plasma NT-
proBNP concentrations are reported to be almost iden-
tical.12 The potential reasons for this discrepancy
between species are not immediately clear. In this
study, plasma NT-proBNP concentrations were signiﬁ-
cantly higher using the second-generation versus the
ﬁrst-generation assay, whereas in contrast NT-proBNP
concentrations in pleural ﬂuid samples were not signiﬁ-
cantly diﬀerent between assay generations. One possible
explanation is that the rate of postsample degradation
is lower in pleural ﬂuid than in plasma samples, per-
haps because of lower concentrations of protease
enzymes. Further studies are necessary to investigate
this possibility.
This study has a number of important limitations.
While attempts were made to collect plasma and pleu-
ral ﬂuid samples at the same time, feline instability
might have caused pleural ﬂuid and blood samples to
be obtained hours apart from each other. Cats were
assigned to the cardiac or noncardiac groups based on
the opinion of the blinded cardiologist, and misclassiﬁ-
cation of cases could have occurred. This study
involved use of diﬀerent sample collection, handling
and storage protocols; however, samples collected for
ELISA from the US cohort were handled according to
current manufacturer recommendations and results
between the US and UK cohorts were comparable.
The pleural ﬂuid POC tests from both the US and UK
cohorts were performed on batched samples which had
been stored at 80°C, and further studies that utilize
the POC test in pleural ﬂuid samples in a truly pet-side
manner, including comparison of assay performance
when used immediately, compared with on previously
frozen samples, should be performed. Pleural ﬂuid
sample POC testing was not performed immediately in
this study because the POC device had not been vali-
dated for use with pleural ﬂuid samples at the time of
sample collection. One disadvantage of using the POC
device is that the result is either positive or negative;
this is in contrast to the quantitative ELISA, which
allows for interpretation of the results throughout a
range of possible values. The POC device is not speciﬁ-
cally designed to diﬀerentiate causes of pleural eﬀusion
in cats, but rather to detect occult cardiomyopathy in
cats without obvious respiratory signs, and the device’s
cut-oﬀ value between a negative and positive result is
relatively low for diﬀerentiation of cardiac versus non-
cardiac etiologies of pleural eﬀusion. Nevertheless, the
POC assay when used with plasma was able to diﬀer-
entiate cause of pleural eﬀusion with good diagnostic
accuracy.
In conclusion, the results of this study suggest that
quantitative measurements of NT-proBNP in plasma
and pleural ﬂuid samples using a second-generation
assay allow diﬀerentiation of cardiac from noncardiac
causes of pleural eﬀusion with good diagnostic accu-
racy. Cut-oﬀ values speciﬁc for sample type should be
used. Measurement of NT-proBNP in plasma samples
using a POC test also allows diﬀerentiation of cardiac
from noncardiac causes of pleural eﬀusion with good
diagnostic accuracy; however, although sensitivity is
excellent and a negative POC result in pleural ﬂuid
samples helps rule out a cardiac cause of pleural eﬀu-
sion, the speciﬁcity of the POC test is low, resulting in
a low positive predictive value. Measurements of NT-
proBNP in plasma ﬂuid samples obtained using the sec-
ond-generation assay are systematically greater than
those obtained using the ﬁrst-generation assay, and cut-
oﬀs speciﬁc to the second-generation assay should be
used.
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Footnotes
a Cardiopet Feline proBNP, IDEXX Laboratories Inc., West-
brook, ME
b SNAP Feline proBNP, IDEXX Laboratories Inc., Westbrook,
ME
c Cardiopet proBNP specimen tubes, IDEXX Laboratories Inc.,
Westbrook, ME
d Mainville et al. Analytical validation of an immunoassay for the
quantiﬁcation of N-terminal pro-B-type natriuretic peptide in
feline blood. Journal of Veterinary Diagnostic Investigation (In
Press).
e SPSS 22; IBM, Armonk NY; MedCalc 15.2.2; MedCalc Soft-
ware, Ostend, Belguim
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